Compare LND & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LND | RZLT |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.6M | 326.4M |
| IPO Year | N/A | 2011 |
| Metric | LND | RZLT |
|---|---|---|
| Price | $3.99 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.17 |
| AVG Volume (30 Days) | 104.4K | ★ 2.1M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.65 | N/A |
| Revenue Next Year | $6.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.47 | $1.07 |
| 52 Week High | $4.45 | $11.46 |
| Indicator | LND | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 43.23 | 39.14 |
| Support Level | $3.95 | $1.87 |
| Resistance Level | $4.39 | $2.82 |
| Average True Range (ATR) | 0.15 | 0.22 |
| MACD | -0.04 | -0.05 |
| Stochastic Oscillator | 13.89 | 24.75 |
Brasilagro - Cia Bras de Prop Agricolas is a Brazil-based company, engaged in the acquisition, development, operation, and sale of rural properties suitable for agricultural activities. The business activity of the firm is operated through Real estate, Grains, Sugarcane, Cattle rising, Cotton, and Other segments. The Grains segment is involved in the production and sale of soybean and corn. The Sugarcane segment includes the sale of raw product. The Real Estate segment presents the P&L from operations carried out in the company's subsidiaries. The Cattle Raising segment consists of producing and selling beef calves after weaning, which characterizes the activity as breeding and the Other segment engages in other corporate activities. The majority of revenue is earned from Grain Segment.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.